Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Caribou Biosciences, Inc.CRBU · Entity 6445 | Chief Scientific Officer | February 20, 2025 | February 22, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Caribou Biosciences, Inc.
Report date February 20, 2025 · Filed February 22, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 435,120 |
Reported balance
After 2025-02-20 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2025-02-20 · Grant · Acquired 37,500 · Balance 435,120 F1: This reflects restricted stock units ("RSUs") that vest in four equal annual installments beginning on February 20, 2026, subject to the reporting person's continued services to the Issuer through the applicable vesting dates. The RSUs will be settled in stock within 30 days after each vesting date. F2: Includes 10,583 shares purchased pursuant to the Issuer's 2021 Employee Stock Purchase Plan on February 15, 2025. |
| Common StockSEC Table I · non-derivative | Direct | 431,556 |
Reported balance
After 2025-02-21 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2025-02-21 · Sale · Disposed 3,564 · Balance 431,556 F3: Reflects the number of shares of common stock that were sold in a "sell to cover" transaction for the sole purpose of satisfying tax withholding obligations in connection with the vesting of RSUs previously granted to the reporting person and does not represent a discretionary trade by the reporting person. This transaction was made pursuant to a Rule 10b5-1 trading plan in the form of a durable sell-to-cover instruction adopted prior to the 2023 amendments to Rule 10b5-1. The trading plan provides for the automatic sale of shares of common stock necessary to satisfy the reporting person's tax withholding obligations incurred in connection with the vesting of RSUs. F4: This transaction was executed in multiple trades on 2/21/2025 at prices ranging from $1.32 to $1.35. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the specified range. |
| Option to purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $1.41 · Expires 2035-02-19 | Direct | 170,000 |
Reported balance
After 2025-02-20 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-02-20 · Grant · Acquired 170,000 · Balance 170,000 F5: 25% of the options will vest upon the one-year anniversary of the grant date, February 20, 2026, and 1/48th will vest monthly thereafter over the 36-month period following the one-year cliff, subject to the reporting person's continued service to the Issuer through the applicable vesting dates. |
Filing footnotes · ownership attribution and instrument terms
F1: This reflects restricted stock units ("RSUs") that vest in four equal annual installments beginning on February 20, 2026, subject to the reporting person's continued services to the Issuer through the applicable vesting dates. The RSUs will be settled in stock within 30 days after each vesting date.
F2: Includes 10,583 shares purchased pursuant to the Issuer's 2021 Employee Stock Purchase Plan on February 15, 2025.
F3: Reflects the number of shares of common stock that were sold in a "sell to cover" transaction for the sole purpose of satisfying tax withholding obligations in connection with the vesting of RSUs previously granted to the reporting person and does not represent a discretionary trade by the reporting person. This transaction was made pursuant to a Rule 10b5-1 trading plan in the form of a durable sell-to-cover instruction adopted prior to the 2023 amendments to Rule 10b5-1. The trading plan provides for the automatic sale of shares of common stock necessary to satisfy the reporting person's tax withholding obligations incurred in connection with the vesting of RSUs.
F4: This transaction was executed in multiple trades on 2/21/2025 at prices ranging from $1.32 to $1.35. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the specified range.
F5: 25% of the options will vest upon the one-year anniversary of the grant date, February 20, 2026, and 1/48th will vest monthly thereafter over the 36-month period following the one-year cliff, subject to the reporting person's continued service to the Issuer through the applicable vesting dates.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 21, 2025 Filed Feb 22, 2025 01:18 UTC | Caribou Biosciences, Inc. CRBU · Entity 6445 | SaleCommon Stock | 3,564 | $1.35 | $4,811.40 |
DisclosureSEC source: 0001871131-25-000003 · wk-form4_1740187088.xml · nonDerivative · entry 2 Kanner Steven · CIK 0001871131 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 431,556 F3 · kind: Reflects the number of shares of common stock that were sold in a "sell to cover" transaction for the sole purpose of satisfying tax withholding obligations in connection with the vesting of RSUs previously granted to the reporting person and does not represent a discretionary trade by the reporting person. This transaction was made pursuant to a Rule 10b5-1 trading plan in the form of a durable sell-to-cover instruction adopted prior to the 2023 amendments to Rule 10b5-1. The trading plan provides for the automatic sale of shares of common stock necessary to satisfy the reporting person's tax withholding obligations incurred in connection with the vesting of RSUs. F3 · shares: Reflects the number of shares of common stock that were sold in a "sell to cover" transaction for the sole purpose of satisfying tax withholding obligations in connection with the vesting of RSUs previously granted to the reporting person and does not represent a discretionary trade by the reporting person. This transaction was made pursuant to a Rule 10b5-1 trading plan in the form of a durable sell-to-cover instruction adopted prior to the 2023 amendments to Rule 10b5-1. The trading plan provides for the automatic sale of shares of common stock necessary to satisfy the reporting person's tax withholding obligations incurred in connection with the vesting of RSUs. F4 · price: This transaction was executed in multiple trades on 2/21/2025 at prices ranging from $1.32 to $1.35. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the specified range. Read SEC document |
| February 20, 2025 Filed Feb 22, 2025 01:18 UTC | Caribou Biosciences, Inc. CRBU · Entity 6445 | GrantOption to purchase Common Stock · Derivative | 170,000 | $0.00 Strike: $1.41 | $0.00 |
DisclosureSEC source: 0001871131-25-000003 · wk-form4_1740187088.xml · derivative · entry 3 Kanner Steven · CIK 0001871131 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 170,000 Underlying: Common Stock · 170,000 shares Expires 2035-02-19 F5 · derivative.exercise_date: 25% of the options will vest upon the one-year anniversary of the grant date, February 20, 2026, and 1/48th will vest monthly thereafter over the 36-month period following the one-year cliff, subject to the reporting person's continued service to the Issuer through the applicable vesting dates. Read SEC document |
| February 20, 2025 Filed Feb 22, 2025 01:18 UTC | Caribou Biosciences, Inc. CRBU · Entity 6445 | GrantCommon Stock | 37,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001871131-25-000003 · wk-form4_1740187088.xml · nonDerivative · entry 1 Kanner Steven · CIK 0001871131 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 435,120 F1 · shares: This reflects restricted stock units ("RSUs") that vest in four equal annual installments beginning on February 20, 2026, subject to the reporting person's continued services to the Issuer through the applicable vesting dates. The RSUs will be settled in stock within 30 days after each vesting date. F2 · balance_after: Includes 10,583 shares purchased pursuant to the Issuer's 2021 Employee Stock Purchase Plan on February 15, 2025. Read SEC document |
| February 20, 2024 Filed Feb 22, 2024 22:15 UTC | Caribou Biosciences, Inc. CRBU · Entity 6445 | GrantOption to purchase Common Stock · Derivative | 153,000 | $0.00 Strike: $6.81 | $0.00 |
DisclosureSEC source: 0001628280-24-006419 · wk-form4_1708640094.xml · derivative · entry 2 Kanner Steven · CIK 0001871131 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 153,000 Underlying: Common Stock · 153,000 shares Expires 2034-02-19 F2 · derivative.exercise_date: 25% of the options will vest upon the one-year anniversary of the grant date, February 20, 2025, and 1/48th will vest monthly thereafter over the 36-month period following the one-year cliff, subject to the reporting person's continued service to the Issuer through the applicable vesting dates. Read SEC document |
| February 20, 2024 Filed Feb 22, 2024 22:15 UTC | Caribou Biosciences, Inc. CRBU · Entity 6445 | GrantCommon Stock | 33,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-006419 · wk-form4_1708640094.xml · nonDerivative · entry 1 Kanner Steven · CIK 0001871131 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 387,037 F1 · shares: This reflects restricted stock units ("RSUs") that vest in four equal annual installments beginning on February 20, 2025, subject to the reporting person's continued services to the Issuer through the applicable vesting dates. The RSUs will be settled in stock within 30 days after each vesting date. Read SEC document |
| February 06, 2024 Filed Feb 8, 2024 22:06 UTC | Caribou Biosciences, Inc. CRBU · Entity 6445 | Exercise / conversionOption to purchase Common Stock · Derivative | 30,577 | $0.00 Strike: $2.69 | $0.00 |
DisclosureSEC source: 0001871131-24-000002 · wk-form4_1707429995.xml · derivative · entry 2 Kanner Steven · CIK 0001871131 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,623 Underlying: Common Stock · 30,577 shares Expires 2029-09-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 1/4th of the shares subject to this option vested on October 1, 2020 and an additional 1/48th of the aggregate number of shares subject to the option have vested or will vest on the corresponding day of each month thereafter, subject to the reporting person's continued services to the Issuer through the applicable vesting dates. Read SEC document |
| February 06, 2024 Filed Feb 8, 2024 22:06 UTC | Caribou Biosciences, Inc. CRBU · Entity 6445 | Exercise / conversionCommon Stock | 30,577 | $2.69 | $82,252.13 |
DisclosureSEC source: 0001871131-24-000002 · wk-form4_1707429995.xml · nonDerivative · entry 1 Kanner Steven · CIK 0001871131 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 354,037 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 21, 2023 Filed Feb 23, 2023 22:13 UTC | Caribou Biosciences, Inc. CRBU · Entity 6445 | GrantOption to purchase Common Stock · Derivative | 131,000 | $0.00 Strike: $6.12 | $0.00 |
DisclosureSEC source: 0001619856-23-000027 · wf-form4_167719039206421.xml · derivative · entry 1 Kanner Steven · CIK 0001871131 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,000 Underlying: Common Stock · 131,000 shares Expires 2033-02-20 F1 · derivative.exercise_date: The shares subject to this option will vest in equal monthly installments starting on the first monthly anniversary of the grant date until the option is fully vested on February 21, 2027, subject to the reporting person's continued service to the Issuer through the applicable vesting dates. Read SEC document |
| December 02, 2022 Filed Dec 3, 2022 00:01 UTC | Caribou Biosciences, Inc. CRBU · Entity 6445 | Exercise / conversionOption to purchase Common Stock · Derivative | 21,401 | $2.69 Strike: $2.69 | $57,568.69 |
DisclosureSEC source: 0001619856-22-000031 · wf-form4_167002566431978.xml · derivative · entry 2 Kanner Steven · CIK 0001871131 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,200 Underlying: Common Stock · 21,401 shares Expires 2029-09-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 1/4th of the shares subject to this option vested on October 1, 2020 and an additional 1/48th of the aggregate number of shares subject to the option have vested or will vest on the corresponding day of each month thereafter, subject to the reporting person's continued services to the Issuer through the applicable vesting dates. Read SEC document |
| December 02, 2022 Filed Dec 3, 2022 00:01 UTC | Caribou Biosciences, Inc. CRBU · Entity 6445 | Exercise / conversionCommon Stock | 21,401 | $2.69 | $57,568.69 |
DisclosureSEC source: 0001619856-22-000031 · wf-form4_167002566431978.xml · nonDerivative · entry 1 Kanner Steven · CIK 0001871131 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 323,460 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 25, 2022 Filed Aug 26, 2022 21:42 UTC | Caribou Biosciences, Inc. CRBU · Entity 6445 | Exercise / conversionOption to purchase Common Stock · Derivative | 43,248 | $0.00 Strike: $2.69 | $0.00 |
DisclosureSEC source: 0001209191-22-047748 · doc4.xml · derivative · entry 3 Kanner Steven · CIK 0001871131 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,601 Underlying: Common Stock · 43,248 shares Expires 2029-09-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 1/4th of the shares subject to this option vested on October 1, 2020 and an additional 1/48th of the aggregate number of shares subject to the option have vested or will vest on the corresponding day of each month thereafter, subject to the reporting person's continued services to the Issuer through the applicable vesting dates. Read SEC document |
| August 25, 2022 Filed Aug 26, 2022 21:42 UTC | Caribou Biosciences, Inc. CRBU · Entity 6445 | SaleCommon Stock | 43,248 | $11.22 | $485,220.94 |
DisclosureSEC source: 0001209191-22-047748 · doc4.xml · nonDerivative · entry 2 Kanner Steven · CIK 0001871131 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 302,059 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 24, 2022. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.88 to $11.37, inclusive. The reporting person undertakes to provide to Caribou Biosciences, Inc., any security holder of Caribou Biosciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) to this Form 4. Read SEC document |
| August 25, 2022 Filed Aug 26, 2022 21:42 UTC | Caribou Biosciences, Inc. CRBU · Entity 6445 | Exercise / conversionCommon Stock | 43,248 | $2.69 | $116,337.12 |
DisclosureSEC source: 0001209191-22-047748 · doc4.xml · nonDerivative · entry 1 Kanner Steven · CIK 0001871131 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 345,307 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 13, 2022 Filed May 18, 2022 00:51 UTC | Caribou Biosciences, Inc. CRBU · Entity 6445 | Exercise / conversionOption to purchase Common Stock · Derivative | 6,114 | $0.00 Strike: $2.69 | $0.00 |
DisclosureSEC source: 0001209191-22-029893 · doc4.xml · derivative · entry 4 Kanner Steven · CIK 0001871131 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,849 Underlying: Common Stock · 6,114 shares Expires 2029-09-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Due to a rounding error, the exercise price for this stock option was inadvertently originally reported as $2.68 per share on the reporting person's Form 3 filed on July 22, 2021. F3 · derivative.exercise_date: 1/4th of the shares subject to this option vested on October 1, 2020 and an additional 1/48th of the aggregate number of shares subject to the option have vested or will vest on the corresponding day of each month thereafter, subject to the reporting person's continued services to the Issuer through the applicable vesting dates. Read SEC document |
| May 13, 2022 Filed May 18, 2022 00:51 UTC | Caribou Biosciences, Inc. CRBU · Entity 6445 | Exercise / conversionOption to purchase Common Stock · Derivative | 68,306 | $0.00 Strike: $1.81 | $0.00 |
DisclosureSEC source: 0001209191-22-029893 · doc4.xml · derivative · entry 3 Kanner Steven · CIK 0001871131 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,534 Underlying: Common Stock · 68,306 shares Expires 2027-07-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 1/4th of the shares subject to this option vested on June 30, 2018 and an additional 1/48th of the aggregate number of shares subject to the option vested on the corresponding day of each month thereafter (or the last day of the month, if there was no corresponding day of the month), subject to the reporting person's continued services to the Issuer through the applicable vesting dates. Read SEC document |
| May 13, 2022 Filed May 18, 2022 00:51 UTC | Caribou Biosciences, Inc. CRBU · Entity 6445 | Exercise / conversionCommon Stock | 6,114 | $2.69 | $16,446.66 |
DisclosureSEC source: 0001209191-22-029893 · doc4.xml · nonDerivative · entry 2 Kanner Steven · CIK 0001871131 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 302,059 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Due to a rounding error, the exercise price for this stock option was inadvertently originally reported as $2.68 per share on the reporting person's Form 3 filed on July 22, 2021. Read SEC document |
| May 13, 2022 Filed May 18, 2022 00:51 UTC | Caribou Biosciences, Inc. CRBU · Entity 6445 | Exercise / conversionCommon Stock | 68,306 | $1.81 | $123,633.86 |
DisclosureSEC source: 0001209191-22-029893 · doc4.xml · nonDerivative · entry 1 Kanner Steven · CIK 0001871131 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 295,945 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 04, 2022 Filed Mar 8, 2022 00:58 UTC | Caribou Biosciences, Inc. CRBU · Entity 6445 | Exercise / conversionOption to purchase Common Stock · Derivative | 1,549 | $0.00 Strike: $4.11 | $0.00 |
DisclosureSEC source: 0001209191-22-016872 · doc4.xml · derivative · entry 4 Kanner Steven · CIK 0001871131 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 230,365 Underlying: Common Stock · 1,549 shares Expires 2031-03-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 1/4th of the shares subject to this option vested on March 2, 2022 and an additional 1/48th of the aggregate number of shares subject to the option will vest on the corresponding day of each month thereafter until the option is fully vested, subject to the reporting person's continued service to the Issuer through the applicable vesting dates. Read SEC document |
| March 04, 2022 Filed Mar 8, 2022 00:58 UTC | Caribou Biosciences, Inc. CRBU · Entity 6445 | Exercise / conversionOption to purchase Common Stock · Derivative | 9,171 | $0.00 Strike: $2.69 | $0.00 |
DisclosureSEC source: 0001209191-22-016872 · doc4.xml · derivative · entry 3 Kanner Steven · CIK 0001871131 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,963 Underlying: Common Stock · 9,171 shares Expires 2029-09-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Due to a rounding error, the exercise price for this stock option was inadvertently originally reported as $2.68 per share on the reporting person's Form 3 filed on July 22, 2021. F3 · derivative.exercise_date: 1/4th of the shares subject to this option vested on October 1, 2020 and an additional 1/48th of the aggregate number of shares subject to the option have vested or will vest on the corresponding day of each month thereafter until the option is fully vested, subject to the reporting person's continued service to the Issuer through the applicable vesting dates. Read SEC document |
| March 04, 2022 Filed Mar 8, 2022 00:58 UTC | Caribou Biosciences, Inc. CRBU · Entity 6445 | Exercise / conversionCommon Stock | 1,549 | $4.11 | $6,366.39 |
DisclosureSEC source: 0001209191-22-016872 · doc4.xml · nonDerivative · entry 2 Kanner Steven · CIK 0001871131 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 227,639 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 04, 2022 Filed Mar 8, 2022 00:58 UTC | Caribou Biosciences, Inc. CRBU · Entity 6445 | Exercise / conversionCommon Stock | 9,171 | $2.69 | $24,669.99 |
DisclosureSEC source: 0001209191-22-016872 · doc4.xml · nonDerivative · entry 1 Kanner Steven · CIK 0001871131 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 226,090 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Due to a rounding error, the exercise price for this stock option was inadvertently originally reported as $2.68 per share on the reporting person's Form 3 filed on July 22, 2021. F2 · balance_after: Includes 1,888 shares purchased pursuant to the Issuer's 2021 Employee Stock Purchase Plan on February 15, 2022 for $9.85 per share. Read SEC document |
| December 20, 2021 Filed Dec 21, 2021 22:29 UTC | Caribou Biosciences, Inc. CRBU · Entity 6445 | GrantOption to purchase Common Stock · Derivative | 147,000 | $0.00 Strike: $15.16 | $0.00 |
DisclosureSEC source: 0001209191-21-070810 · doc4.xml · derivative · entry 1 Kanner Steven · CIK 0001871131 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,000 Underlying: Common Stock · 147,000 shares Expires 2031-12-19 F1 · derivative.exercise_date: The shares subject to this option will vest in equal monthly installments starting on the first monthly anniversary of the grant date until the option is fully vested on December 20, 2025, subject to the reporting person's continued service to the Issuer through the applicable vesting dates. Read SEC document |
| October 12, 2021 Filed Oct 13, 2021 23:31 UTC | Caribou Biosciences, Inc. CRBU · Entity 6445 | OtherOption to purchase Common Stock · Derivative | 14,614 | $0.00 Strike: $2.69 | $0.00 |
DisclosureSEC source: 0001209191-21-060424 · doc4.xml · derivative · entry 6 Kanner Steven · CIK 0001871131 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,134 Underlying: Common Stock · 14,614 shares Expires 2029-09-30 F2 · derivative.exercise_price: The exercise price for this stock option was incorrectly reported as $2.68 per share on the reporting person's Form 3 filed on July 22, 2021. F4 · derivative.exercise_date: 1/4th of the shares subject to this option vested on October 1, 2020 and an additional 1/48th of the aggregate number of shares subject to the option have vested or will vest on the corresponding day of each month thereafter, subject to the reporting person's continued services to the Issuer through the applicable vesting dates. Read SEC document |
| October 12, 2021 Filed Oct 13, 2021 23:31 UTC | Caribou Biosciences, Inc. CRBU · Entity 6445 | OtherOption to purchase Common Stock · Derivative | 698 | $0.00 Strike: $1.81 | $0.00 |
DisclosureSEC source: 0001209191-21-060424 · doc4.xml · derivative · entry 5 Kanner Steven · CIK 0001871131 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,879 Underlying: Common Stock · 698 shares Expires 2028-03-07 F3 · derivative.exercise_date: This option became fully exercisable on June 30, 2021. Read SEC document |
| October 12, 2021 Filed Oct 13, 2021 23:31 UTC | Caribou Biosciences, Inc. CRBU · Entity 6445 | OtherOption to purchase Common Stock · Derivative | 99,548 | $0.00 Strike: $1.81 | $0.00 |
DisclosureSEC source: 0001209191-21-060424 · doc4.xml · derivative · entry 4 Kanner Steven · CIK 0001871131 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,840 Underlying: Common Stock · 99,548 shares Expires 2027-07-11 F3 · derivative.exercise_date: This option became fully exercisable on June 30, 2021. Read SEC document |
| October 12, 2021 Filed Oct 13, 2021 23:31 UTC | Caribou Biosciences, Inc. CRBU · Entity 6445 | PurchaseCommon Stock | 14,614 | $2.69 | $39,311.66 |
DisclosureSEC source: 0001209191-21-060424 · doc4.xml · nonDerivative · entry 3 Kanner Steven · CIK 0001871131 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 215,031 F1 · kind: These shares were acquired pursuant to the exercise of a stock option, as reported in Table II below. F2 · price: The exercise price for this stock option was incorrectly reported as $2.68 per share on the reporting person's Form 3 filed on July 22, 2021. Read SEC document |
| October 12, 2021 Filed Oct 13, 2021 23:31 UTC | Caribou Biosciences, Inc. CRBU · Entity 6445 | PurchaseCommon Stock | 698 | $1.81 | $1,263.38 |
DisclosureSEC source: 0001209191-21-060424 · doc4.xml · nonDerivative · entry 2 Kanner Steven · CIK 0001871131 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,417 F1 · kind: These shares were acquired pursuant to the exercise of a stock option, as reported in Table II below. Read SEC document |
| October 12, 2021 Filed Oct 13, 2021 23:31 UTC | Caribou Biosciences, Inc. CRBU · Entity 6445 | PurchaseCommon Stock | 99,548 | $1.81 | $180,181.88 |
DisclosureSEC source: 0001209191-21-060424 · doc4.xml · nonDerivative · entry 1 Kanner Steven · CIK 0001871131 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 199,719 F1 · kind: These shares were acquired pursuant to the exercise of a stock option, as reported in Table II below. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.